Eric W. Kimble

Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.

The National Psoriasis Foundation is a non-profit organization that aims to provide assistance to individuals suffering from psoriasis and psoriatic arthritis. The private company is based in Portland, OR. The company strives to help patients get the necessary treatment while also promoting research to find a cure for these conditions.

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.